

d) adding a test compound to said hollow fiber bioreactor, and determining the effects of said test compound on the lytic organism.

30. A hollow fiber bioreactor comprising: multiple hollow fibers arranged to form an extracapillary space (ECS); a stable cell line growing in said ECS at a density of at least  $10^6$  cells per milliliter; and a lytic organism of a type capable of infecting and lysing cells of said stable cell line.

*Ad J*

*cont*

31. A method according to claim 30 where said stable cell line is selected from mammalian cell lines, insect cell lines, yeast cell lines and bacterial cell lines.

#### REMARKS

Currently claims 15-31 are pending. Claims 1-14 have been canceled. The claims have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependency. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Frank P. Grassler  
Attorney for Applicants  
Registration No. 31,164

Date: 12/11/31  
GlaxoSmithKline Inc.  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Phone: 919-483-2482  
Facsimile: 919-483-7988